A New Year, but the Same Old Stock Market
The new year was to have brought a new beginning for China's stock market. Instead, investors who were set to welcome the return of IPO action after a suspension of 14 months were disappointed by news on January 10 that Jiangsu Aosaikang Pharmaceutical Co. Ltd. was putting its anticipated initial public offering on hold.
The abrupt postponement has sparked questions about the regulator's reform agenda. Clearly, at a time when it is trying to clarify its own role vis-à-vis the market, the regulator has yet to master the art of timing. Xiao Gang, chairman of the China Securities Regulatory Commission, said at a work conference this month that reform will see a complete overhaul of the regulator's scope of oversight of the capital market. Its recent actions must be seen in light of this pledge.
- Without Wages
- The Fall of Language in the Age of English
- Ticket to Childhood
- Taking the Next Step in Power Industry Reform
- Protesting Times
- Knives Out
- Men Have Better Chance than Women to Get Job Interview, Study Finds
- Party Legend's Son Denies He Is De Facto Head of Insurance Firm
- Alibaba's Bickering with Gov't Saps Investor Confidence
- Tencent Tops List of China's Most Valuable Brands
- Sign up to receive our free daily newsletter
- Scandal-Hit GlaxoSmithKline 'to Lay Off 1,000 Employees in China'
- Gov't Had Reservations about Selling Stake in Citic Ltd. to Foreigners
- Caught in Rising China's Centrifuge
- Two-Thirds of Provinces Say They Missed GDP Growth Targets in 2014
- Downfall of Party Internet Policeman 'Helped Lead to National Cleanup Campaign'
- Lanzhou Shames CNPC Unit for Pollution Crises
- Embattled Founder Securities 'Cannot Reach Its Chairman'
- Gov't Digs Into Soil Pollution Problem with Proposal for New Standards
- Banks Trying Direct Route to Online Future
- Taobao, Gov't Get Real Testy over Fake Goods Accusations